The present disclosure provides a method for increasing the bulk density of a nicotinamide mononucleotide crystal and a crystal thereof. The method includes: dissolving nicotinamide mononucleotide in water to obtain an aqueous solution of nicotinamide mononucleotide; performing vacuum concentration or freeze drying on the aqueous solution of nicotinamide mononucleotide to obtain a semi-solid with a water content equal to or less than 15%; adding a solventing-out agent dropwise to the semi-solid under stirring, and meanwhile, performing cooling at a rate of 1-15° C./h to a crystallization end temperature of 5-18° C.; and after a crystal is completely precipitated, performing filtration and drying on the crystal to obtain a nicotinamide mononucleotide crystal with increased bulk density. An NMN crystal of a bulk structure can be prepared by the method, and compared with existing NMN crystals, the bulk density of the NMN crystal is doubled.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemicals, namely, ß-Nicotinamide Mononucleotide (ß-NMN), ß-Nicotinamide mononucleotide, reduced form disodium salt, and ß-Nicotinamide Adenine Dinucleotide (ß-NAD); Industrial chemicals; Vitamins for the food industry; Vitamins for use in the manufacture of food supplements; Vitamins for use in the manufacture of pharmaceuticals
3.
METHOD FOR INCREASING BULK DENSITY OF CRYSTAL OF NICOTINAMIDE MONONUCLEOTIDE, AND CRYSTAL OF NICOTINAMIDE MONONUCLEOTIDE
A method for increasing the bulk density of a crystal of nicotinamide mononucleotide (NMN), and a crystal of NMN. The method comprises: dissolving NMN in water to obtain an aqueous solution of NMN; subjecting the aqueous solution of NMN to concentration under reduced pressure or freeze drying same to obtain a semisolid with a water content of less than 15%; adding a solventing-out agent to the semisolid in a dropwise manner while stirring same, and at the same time, cooling same to a terminal crystallization temperature of 5°C - 18°C at a cooling rate of 1°C/h - 15°C/h; and after the crystal is completely precipitated, filtering and drying the crystal to obtain the crystal of NMN having an increased bulk density. A crystal of NMN having a bulk structure can be prepared by means of the method, and the bulk density of the crystal of NMN is increased by multiple times compared with the existing crystal of NMN.
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
4.
Method for preparing nicotinamide mononucleotide cocrystal
The present disclosure provides a method for preparing a nicotinamide mononucleotide cocrystal, and aims to solve the technical problems of larger content/weight difference and inconsistent quality of nicotinamide mononucleotide (NMN) medicines or health care products due to poor fluidity of existing nicotinamide mononucleotide crystals. The method includes the steps of mixing nicotinamide mononucleotide as an active pharmaceutical ingredient with isonicotine as a cocrystal former by adopting solution synthesis and then performing crystal precipitation. The method has the advantages of simple operation and wide application range.
The present disclosure aims to solve the technical problems of larger content/weight difference and inconsistent quality of nicotinamide mononucleotide (NMN) medicines or health care products due to poor fluidity of existing nicotinamide mononucleotide crystals, and provides a nicotinamide mononucleotide-isonicotine cocrystal. Cu-Kαradiation is used for the cocrystal, and X-ray powder diffraction represented by an angle 2θ has diffraction peaks at 9.6±0.2°, 13.3±0.3°, 22.8±0.2° and 36.5±0.2°. The cocrystal has a higher bulk density than existing crystals, thereby significantly improving the fluidity of the nicotinamide mononucleotide. Therefore, the technical problems of larger content/weight difference and inconsistent quality of the NMN medicines or health care products in the production of enterprises may be well solved.
The invention relates to a method for preparing nicotinamide mononucleotide by using nicotinamide as a raw material, which comprises: in acetonitrile, dichloromethane, 1,2-dichloroethane or liquid sulfur dioxide as a solvent, allowing nicotinamide and tetraacetyl ribose to react as catalyzed by trimethylsilyl trifluoromethanesulfonate or tin tetrachloride, adjusting a pH value thereof to 3-5, adding a sodium methoxide solution thereto to react at −15° C. to 5° C., adjusting a pH value thereof to 3-5, and subjecting the reaction mixture to microfiltration and nanofiltration using a membrane concentrator, thereby obtain a nicotinamide ribose solution; allowing the nicotinamide ribose solution to react as catalyzed by nicotinamide ribokinase in the presence of Mg ions, ATP and a buffer, thereby obtaining nicotinamide mononucleotide. The method of the invention omits the step of refining nicotinamide ribose, and thus has simpler process, lower cost and less time consumption, and has the advantages of faster reaction speed and lower enzyme consumption compared with the enzyme catalytic process directly using refined nicotinamide ribose solid.
A semi-synthesis method for apigenin. The method comprises: with dimethyl sulfoxide as a solvent, reacting naringenin with iodine at a temperature of 100-120°C; adding sodium hydrosulfite or a Baoyuan powder and an aqueous solution of ethanol with a volume fraction of 25-50% to the reaction solution, and then reacting same in an alkaline environment at a temperature of 70-90°C; filtering the reaction solution while same is still hot, collecting a filtrate, and adjusting the temperature to 30-40°C and the pH value to 6-7; and adding an aqueous solution of ethanol with a volume fraction of 50-80%, and after a crystal is precipitated out, filtering same, and collecting a filter cake to obtain the apigenin product. The method has mild reaction conditions, is easy to control, has simple steps, convenient operations, a short time consumption, a low cost, a high yield, and creates no environmental pollution.
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
8.
METHOD FOR PREPARING NICOTINAMIDE MONONUCLEOTIDE BY USING NICOTINAMIDE AS RAW MATERIAL
A method for preparing nicotinamide mononucleotide by using nicotinamide as a raw material, the method comprising: in a solvent of acetonitrile, dichloromethane, 1,2-dichloroethane or a liquid sulfur dioxide, catalyzing the reaction of nicotinamide and tetraacetylribose with trimethylsilyl trifluoromethanesulfonate or tin tetrachloride, adjusting the pH value to 3-5, adding a sodium methoxide solution, reacting same at -15°C-5°C, adjusting the pH value to 3-5, and performing microfiltration and nanofiltration treatments with a membrane concentration apparatus, so as to obtain a nicotinamide ribose solution; and in an environment where Mg ions, ATP and a buffer are present, catalyzing the reaction of the nicotinamide ribose solution with nicotinamide ribokinase, so as to obtain the nicotinamide mononucleotide. The method reduces the steps of refining nicotinamide ribose, has a simpler process, a lower cost and a shorter time consumption, and has the advantages of a faster reaction speed and a lower enzyme usage amount compared with an enzyme catalytic process of directly refining a solid with nicotinamide ribose.
Disclosed are a method for removing water-soluble phosphates and the use thereof. The method comprises: adding alkali earth metal ions and ammonium ions to a solution to be treated, or adding substances that can produce alkali earth metal ions and ammonium ions in the solution to be treated, adjusting the pH value of the solution until a precipitate forms, and then removing the precipitate from the solution. The use refers to applying the method to the production of a water-soluble coenzyme, for removing impurity phosphate ions produced during the production of the water-soluble coenzyme. The method has a simple process, mild conditions, a short consumption time and a high removal rate, and does not affect the yield of the product.
C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
10.
METHOD FOR RESISTING VISCOSITY DURING ENZYME-CATALYZED PRODUCTION OF PHOSPHATIDYLSERINE AND METHOD FOR PRODUCING PHOSPHATIDYLSERINE USING SAME
Provided is a method for resisting viscosity during enzyme-catalyzed production of phosphatidylserine, comprising: adding an ethanol solution with a pH value of 7.5-9.5 into a crude product obtained during enzyme-catalyzed production of phosphatidylserine, uniformly mixing, carrying out solid-liquid separation, and collecting the solid. The method can significantly reduce the viscosity of an enzyme reaction liquid. Also provided is a method for producing phosphatidylserine using the method for resisting viscosity, comprising: mixing natural phospholipids containing phosphatidylcholine with water, L-serine, calcium chloride, and phospholipase D, and stirring at 39-43℃ and reacting for 8-10 h; and collecting a solid after the reaction is finished, then adding an ethanol solution with a pH value of 7.5-9.5, uniformly mixing, collecting the solid, and drying to obtain the phosphatidylserine product. The method improves the single-batch production capacity, reduces the L-serine feeding amount, and reduces production costs.
Provided is a method for improving the transesterification activity of phospholipase D, the method comprising: adding an alcohol substance to an enzymatic reaction system for the enzyme-catalyzed production of phosphatidylserine, wherein the alcohol substance is a short-chain primary and/or secondary alcohol. The method can rapidly increase the rate of the enzyme-catalyzed reaction and reduce the amount of an enzyme; furthermore, the reaction time is reduced by at least half. The method has universal applicability. Further provided is a method for the enzyme-catalyzed production of phosphatidylserine, the method comprising: mixing a natural phospholipid containing phosphatidylcholine with water, L-serine, calcium chloride, an alcohol substance and phospholipase D, and stirring and reacting same at 39-43°C for 4-6 h, wherein the alcohol substance is a short-chain primary and/or secondary alcohol. The method has the advantages of a short enzymatic reaction time, a high conversion rate, and a low production cost.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
12.
METHOD FOR SYNTHESISING CHENODEOXYCHOLIC ACID AND APPLICATION THEREFOR
A method for synthesising chenodeoxycholic acid and an application therefor, relating to the technical field of pharmaceutical and chemical product synthesis, and used for solving the technical problem of the high production costs of existing methods for producing chenodeoxycholic acid. The present method uses phocacholic acid, which has a wide range of sources and low price, as the starting raw material and, by means of a chemical synthesis method, sequentially converts same into the compound shown in formula 3, the compound shown in formula 4, and the compound shown in formula 5, and finally converts the compound shown in formula 5 into chenodeoxycholic acid; the present method can be used in the industrial production of ursodeoxycholic acid and derivatives thereof.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
13.
RECOMBINANT NAD SYNTHETASE AND GENE AND USE THEREOF
Provided are a recombinant NAD synthetase and a gene and use thereof. Said enzyme comprises a nicotinamide mononucleotide adenosyltransferase domain from Haemophilus influenzae and a nicotinamide ribokinase domain from any one of human, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium, and can be used in industrial production to produce NAD on a large scale by using NR and ATP as raw materials.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/39 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts
An enzymatic method for the industrial production of NAD. The method uses nicotinamide ribose (NR) and ATP as raw materials and conducts a biocatalytic reaction in the presence of NAD synthetase to produce NAD, wherein, the NAD synthetase comprises a nicotinamide mononucleotide adenosine transferase structure domain derived from Haemophilus influenzae as well as a nicotinamide ribokinase structure domain derived from any among humans, Saccharomyces cerevisiae, Escherichia coli, and Salmonella typhimurium. The method may achieve one-step catalytic production of NAD using NR and ATP as raw materials.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
15.
SYSTEM FOR LARGE-SCALE PRODUCTION OF RH2 BY MEANS OF ENZYMATIC METHOD
Disclosed is a system for large-scale production of Rh2 by means of an enzymatic method. The production system comprises a reaction kettle, a cooling water circulation device, a hot steam circulation device, an acid storage tank, an alkali storage tank, a measurement device for measuring the degree of reaction in the reaction kettle, a primary solid-liquid separation device for solid-liquid separation treatment of the material from the reaction kettle, a washing tank for cleaning the material subjected to primary solid-liquid separation, a secondary solid-liquid separation device for solid-liquid separation treatment of the material from the water washing tank, and a drying device for drying the material subjected to secondary solid-liquid separation. The production system has a simple structure, complete functions and a compact layout, saves the space and costs, can implement automatic control of a temperature and a pH value, and saves labor.
A method for preparing a mixture of rare ginsenosides Rh3 and Rk2 and a mixture thereof. In the method, Rg3 is used as a raw material, β-glucosidase is used for enzymatic preparation, an acidification reaction is performed after an enzyme-catalyzed reaction is finished, and then solvent extraction is performed to separate a crude product of the mixture of Rh3 and Rk2. The proportion of Rk2 in the mixture is higher than that of Rh3.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Insect-repellents; Poultices; Adult diapers; All purpose disinfectants; Babies' diapers; Breast pads; Diapers for pets; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Dietary supplements; Disinfecting handwash; Herbicides, insecticides, pesticides and fungicides for home, garden and lawn use and for professional use; Medical and surgical dressings; Nursing pads; Nutritional supplements consisting primarily of iron, calcium, zinc; Personal sexual lubricants; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Sanitary napkins; Sanitizing wipes; Vitamin and mineral supplements
18.
Stable nicotinamide riboside composition and preparation method thereof
A nicotinamide riboside composition and preparation method thereof, the icotinamide riboside composition comprises nicotinamide riboside and/or a salt thereof and konjac glucomannan or rebaudioside A. The nicotinamide riboside composition provided by the present invention, used to increase the concentration of NAD in cells, thereby preventing and improving various unhealthy conditions caused by NAD deficiency. is stable in property and easy to store and transport.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A method for preparing a radix puerariae extract from the leftover material of radix puerariae, comprising enzymatic hydrolysis reaction, solvent extraction, filtration, concentration, and drying.
A method for preparing a radix codonopsis extract from a radix codonopsis leftover material, comprising: first adding water, cellulose, and β-glucosidase in the radix codonopsis leftover material; uniformly mixing and carrying out enzymatic hydrolysis; and then extracting with a solvent, filtering, concentrating, and drying to obtain the radix codonopsis extract. The amount of β-glucosidase added is 1-1.5 times that of the cellulose. The method has the advantages of saving resources, low cost, and high active ingredient content of the extract, etc.
An acid phosphatase mutant, and method for preparing nicotinamide riboside by same. The mutant is a protein of the following (a), (b) or (c): (a) a protein, having an amino acid sequence shown in SEQ ID NO: 3; (b) a protein, derived from (a), having catalytic activity higher than an acid phosphatase parent having an amino acid sequence shown in SEQ ID NO: 2, obtained by substituting, deleting or adding several amino acids in the amino acid sequence shown in SEQ ID NO: 3, using nicotinamide mononucleotide as a substrate; (c) a protein, having catalytic activity higher than the acid phosphatase shown in SEQ ID NO: 2, having 90% or more homology with the amino acid sequence of the protein defined by (a) or (b), and using nicotinamide mononucleotide as a substrate. It is used to prepare nicotinamide riboside and the conversion rate can be 99%.
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Li, Zhenwei
Liu, Wenshan
Tang, Xiaoxin
Zhu, Zhiqiang
Abstract
Disclosed are a phospholipase D mutant, a use thereof and a method for preparing phosphatidylserine by means of same, which relate to the technical field of bio-enzyme catalysis. Provided is a phospholipase D mutant with an enzyme activity inclined more towards a phosphatidyl transfer activity. Compared with the amino acid sequence of wild-type phospholipase D, the phospholipase D mutant has a mutation at at least one position selected from positions 93, 105, 215, 216, 228 and 486.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
JIANGXI BONZYMES BIOTECHNOLOGY CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Wenshan
Liu, Yufeng
Li, Zhenwei
Abstract
Provided are a UDP-glucosyltransferase mutant, the use thereof and a method for preparing rebaudioside D. A series of mutants comprising SEQ ID NO: 3 are obtained by subjecting gene sequences of wild-type UDP-glucosyltransferase to site-directed mutagenesis, and the enzyme activity and pH stability of these mutants are improved compared with the wild-type parent.
A method for preparing luteolin, comprising: fully dissolving rutin in an alkaline solution with pH≥10; adding 5-24 equivalents of a reducing agent consisting of thiourea dioxide, potassium chloride, and potassium carbonate in the feeding amount of rutin, and stirring until the solution becomes clear; and controlling reaction at a temperature of 60-90°C for 1-2 hours to obtain the luteolin. The method is simple in process, low in costs, mild in reaction conditions, short in time consumption and high in yield, and is suitable for industrial production.
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
25.
Method and enzyme for preparation of enzyme-modified stevia sugar and use of enzyme-modified stevia sugar
Aspergillus japonicus. The preparation method takes a short time, is efficient and convenient to operate, low in cost, high in conversion rate, green and environmentally friendly, and can be widely applied to industrial scale production. The present invention further provides an enzyme for preparation of the enzyme-modified stevia sugar and application thereof.
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
26.
NADH compound composition, and preparation and use thereof
An NADH compound, and a formulation and use thereof, relating to the technical field of biomedicine and health care products. The NADH compound includes NADH or its physiologically acceptable salt and L-carnitine or its physiologically acceptable salt, and can be used as a weight loss product. The NADH compound has an increased effect in weight loss, and may achieve long-term drug administration of the product.
A method for preparing high-purity NAD, comprising: adjusting a pH value to 6.0-8.0, removing insoluble substances, heating to 35 ± 1°C, adding ethanol, cooling to 6 ± 0.5°C, crystallizing, filtering, heating a filtrate to 25-30°C, adjusting the pH value to 1.5-3.0, adding an NAD seed crystal, cooling to 12 ± 0.5°C, crystallizing, adding ethanol again after crystallinity reaching 40%, cooling to 3 ± 0.5°C, crystallizing, filtering after the crystallinity being above 90%, and drying a filter cake to obtain a high-purity NAD product.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
A method for preparing high-purity riboflavin sodium phosphate, comprising: adjusting the pH value to 5.0-7.0; controlling the solution temperature at 20-40℃, and adding an ethanol aqueous solution with a concentration of 95％ (ml/ml); reducing the temperature to 3-5℃ and waiting for a solid to precipitate; filtering the solid, and drying a filter cake to obtain a pure product, the riboflavin sodium phosphate. The method is suitable for the large-scale isolation and purification of a riboflavin sodium phosphate product with a purity of at least 99% from a biological enzyme reaction liquid or biological fermentation broth.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Guo, Xinglin
Chen, Xiaochun
Abstract
Disclosed is a method of separating and purifying icariin from Epimedium extract, relating to the technical field of separating and purifying a single component from a plant extract, and is intended to address the issues of complicated processing, high preparation costs, and environmental pollution in existing methods. The method comprises: 1) blending an Epimedium extract with an aqueous acetone solution having a volume fraction of 88%-96%; 2) filtering and collecting a filter cake, and then dissolving the filter cake in an aqueous ethanol solution having a volume fraction of 50%-75%; 3) after the dissolution is completed, filtering and collecting the filtrate, and concentrating the filtrate to remove the ethanol, thereby obtaining a concentrated liquid; 4) at a first temperature, adding acetone to the concentrated liquid, mixing uniformly, and lowering the temperature to a second temperature after sufficient dissolution to perform crystallization; 5) after the crystallization is completed, filtering and collecting a filter cake, and letting the filter cake dry to obtain crude icariin. The method can provide a single component having a icariin content of more than 98% that satisfies the high purity requirement of injection.
Provided are an acid phosphatase mutant, an application thereof, and a method for preparing nicotinamide riboside, wherein the conversion rate is more than 99%.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
31.
STABLE NICOTINAMIDE RIBOSIDE COMPOSITION AND PREPARATION METHOD THEREFOR
A nicotinamide riboside composition and a preparation method therefor, said composition including nicotinamide riboside and/or a salt thereof, and konjac glucomannan or rebaudioside A.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Zhang, Qi
Zhang, Dongmin
Fu, Rongzhao
Abstract
The present invention relates to a process for purifying crude NADPH product prepared by biocatalysis. The objective of the present invention is to solve the technical problems of low yield and low purity of the purified product in the existing ion exchange resin method. The present invention comprises sequentially the following steps: pretreatment, loading onto an ion column, elution of cations, pre-elution of impurities etc. The yield of the purification process disclosed in the present invention can be up to 85% or higher and the purified NADPH has a purity of up to 98% or higher.
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
33.
METHOD FOR PREPARING BAOHUOSIDE I BY USING β-GLUCOSIDASE
C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Cao, Lei
Liu, Taotao
Guo, Xinglin
Abstract
Provided is a method for preparing Baohuoside I by using β-glucosidase, comprising catalyzing hydrolysis of a substrate by β-glucosidase to prepare Baohuoside I, the substrate being one or more of Epimedium extract, Icariin, Epimedin A, Epimedin B, Sagittatoside A, and Sagittatoside B, and the β-glucosidase having an amino acid sequence as shown by SEQ ID NO: 2. The method can hydrolyze Epimedium, Epimedin A, Epimedin B, Sagittatoside A, and Sagittatoside B into Baohuoside I, thereby improving the effective utilization rate of Epimedium extract, and greatly reducing the preparation cost of Baohuoside I. Also provided is application of β-glucosidase and a microbial strain containing a β-glucosidase gene in catalyzing hydrolysis of one or more of Epimedium extract, Icariin, Epimedin A, Epimedin B, Sagittatoside A, and Sagittatoside B so as to prepare Baohuoside I.
C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
35.
PREPARATION METHOD FOR REBAUDIOSIDE A, ENZYME FOR REBAUDIOSIDE A PREPARATION, AND APPLICATION
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Li, Zhenwei
Liu, Wenshan
Liu, Yufeng
Abstract
Provided is a preparation method for rebaudioside A, said method comprising: in the presence of uridine diphosphate glucose and a glycosyltransferase, using a steviol glycoside raw material as a substrate to prepare a reaction solution, and stirring and reacting at a constant temperature of 20-45°C to obtain rebaudioside A. The steviol glycoside raw material comprises stevioside, and the glycosyltransferase comprises the amino acid sequence shown in SEQ ID NO: 1. Also provided are an enzyme for rebaudioside A preparation, and an application.
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
Provided is a preparation method for L-alanyl-L-glutamine, said method comprising: in the presence of α-amino acid ester acyltransferase, using L-alanine methyl ester hydrochloride and L-glutamine as substrates to prepare a reaction solution, adjusting the pH of the reaction solution to 7.0-9.0, and after reacting at a constant temperature of 20-40°C, collecting L-alanyl-L-glutamine. The α-amino acid ester acyltransferase is derived from elizabethkingia meningoseptica, and the amino acid sequence of the α-amino acid ester acyltransferase comprises the amino acid sequence in any one of SEQ ID NO: 1 – SEQ ID NO: 6. The preparation method is highly effective, simple, low-cost and environmentally friendly, has a high conversion rate, and may be widely applied in industrial scale production. Also provided are an enzyme for L-alanyl-L-glutamine preparation, and an application.
Disclosed in the present invention is a method for enzymatic synthesis of chloramphenicol intermediate. In the method, nitrobenzaldehyde and glycine are used as substrates, and are reacted under the catalysis of aldolase to obtain a chloramphenicol intermediate. According to the method for preparing a chloramphenicol intermediate provided by the present invention, from inexpensive raw materials that are easily obtained, a chloramphenicol intermediate is obtained by reacting substrates nitrobenzaldehyde and glycine using an aldolase. By means of the reaction, the costs of raw materials are reduced, and the disadvantages in the prior art, such as complicated operation, large pollution, and low yield are overcome. The method provided by the present invention has high conversion rate and high yield of target products, and simplifies the process for preparing chloramphenicol intermediates; the aldolase used can be easily obtained by fermentation using Escherichia coli; the method is lower in production costs and better in product quality than a chemical method, and is suitable for industrial production.
A PRPP quantitative detection method, relating to the technical field of detection methods for specific substances. HPLC is used in the method for performing detection, and chromatographic conditions are as follows: triazolyl bonded silica gel is used as a filler for a chromatographic column, a mobile phase consists of a phase A and a phase B, the phase A is a buffer solution with a pH of 6.0-6.8, the phase B is a solvent with a polarity of 4-7 and capable of being mutually soluble with water and dissolving the PRPP, the percent by volume of the phase A in the mobile phase is 35-50%, and a differential detector is used for implementing detection.
An NADH compound, and a formulation and application thereof, relating to the technical field of biomedicine and health care products. The NADH compound comprises NADH or its physiologically acceptable salt and L-carnitine or its physiologically acceptable salt, and can be used as a weight loss product.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Zhang, Guiwei
Jiang, Ming
Abstract
Terrabacterginsenosidimutansginsenosidimutans to perform a catalytic reaction; the temperature of the catalytic reaction is 25-50°C, and the pH value is 6.5-9.5. Further disclosed are glucosidase and variants thereof.
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Jiang, Ming
Liu, Yufeng
Liu, Wenshan
Chen, Xiaochun
Abstract
A preparation method for enzyme-modified stevioside is provided in the invention and comprises: adding beta-fructofuranosidase into a solution having a stevioside raw material and sucrose dissolved therein so as to obtain a reaction liquid, adjusting the pH of said reaction liquid to 5.0-8.0, maintaining the reaction temperature at 20-45°C, and, after stirring and reacting, collecting the enzyme-modified stevioside, the stevioside raw material comprising one or more of stevioside and rebaudioside A, and the beta-fructofuranosidase being derived from microbacterium saccharophilum or aspergillus japonicus. The preparation method is highly effective and simple, low in cost, requires little time, has a high conversion rate, is environmentally friendly, and may be widely applied in industrial scale production. The enzyme for said preparation method and the application thereof are also provided in the present invention.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
42.
Nicotinamide phosphoribosyltransferase (NAMPT) mutant and use thereof
The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Liu, Taotao
Cao, Lei
Guo, Xinglin
Abstract
Provided is a preparation method for hesperetin, comprising: suspending hesperidin or neohesperidin in water, and adding a sodium hydroxide solution until the hesperidin or neohesperidin is completely dissolved to obtain a substrate preparation solution; adding the substrate preparation solution to an α-L-rhamnosidase and β-glucosidase-containing buffer solution at a speed of 0.1-1mL/min by means of a substrate flow addition method for stirring and reacting to obtain a reaction solution, the reaction continuing for 0.5-1h after the flow addition has finished, the pH of the reaction solution being 6.0-7.0, the reaction temperature being maintained at 45-65°C, the α-L-rhamnosidase being derived from streptomyces, the β-glucosidase being derived from thermotoga petrophila; adjusting the pH of the reaction solution to 3.0-5.0 so that a solid product completely precipitates, collecting the solid product, and obtaining hesperetin. The method is highly effective, simple, environmentally friendly, and suitable for industrial large-scale production.
C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
44.
COMPOSITION CONTAINING NADH AND NADPH AND APPLICATION THEREOF
A composition containing nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) and an application thereof, wherein the composition comprises an active ingredient NADH or a physiologically acceptable salt thereof and NADPH or a physiologically acceptable salt thereof; the weight ratio of NADH or the physiologically acceptable salt thereof to NADPH or the physiologically acceptable salt thereof is 1:0.1-1:1. The described composition may be used to prepare a drug or healthcare product for the treatment of phenylketonuria and tinnitus.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A preparation method for dehydroepiandrosterone, comprising: in a protective atmosphere, adding potassium tert-butoxide to tert-butanol, stirring evenly, adding 4-androstenedione to obtain a mixture, and adding the mixture dropwise to a sodium ascorbate-containing acetic acid solution for a reaction to obtain 5-androstenedione; dissolving the 5-androstenedione in an organic solvent, adding a ketone reductase, a glucose dehydrogenase, glucose and a redox coenzyme to obtain a mixture, controlling the pH of the mixture to be 6.0-6.3, stirring and reacting for 1-6 hours at 22-26°C to obtain a reaction solution, and performing separation and purification on the reaction solution to obtain dehydroepiandrosterone, the ketone reductase and the glucose dehydrogenase being coexpressed by a microbial strain and added in the form of a crude enzyme solution. The synthesis process of the preparation method has few steps, simple operations, high yields and low costs, and may be widely applied to industrial scale production. Also provided is an enzyme for preparation.
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO. , LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Jiang, Ming
Liu, Yufeng
Abstract
A method for preparing ursodeoxycholic acid via a chemical-enzymatic process, comprising: adding hyodeoxycholic acid to a first organic solvent, and oxidising under the effect of an oxidising agent to obtain 6-oxo-lithocholic acid; adding the 6-oxo-lithocholic acid and a sulphonyl hydrazide derivative to a second organic solvent, so that the 6-oxo-lithocholic acid and the sulphonyl hydrazide derivative undergo a nucleophilic addition-elimination reaction to obtain a hydrazone compound; in an inert gas environment, using a reducing agent to reduce the hydrazone compound to obtain lithocholic acid; performing a hydroxylation reaction on the lithocholic acid under the catalytic effect of a hydroxylase and a coenzyme to obtain ursodeoxycholic acid. The method uses hyodeoxycholic acid as an initial raw material, and obtains ursodeoxycholic acid via a three-step chemical process and a one-step biological enzymatic process. The overall synthesis process has few steps, simple operations, high yields and low costs, and may be widely applied to industrial scale production.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
47.
Nicotinamide phosphoribosyltransferase (NAMPT) mutant and use thereof
The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent.
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO.,LTD. (China)
Inventor
Fu, Rongzhao
Liu, Lihui
Yan, Xin
Abstract
A purification method for ginsenoside Rh2, used for purifying an enzyme reaction liquid that prepares Rh2 by catalyzing Rg3 with β-glucosidase, aims at solving the technical problem in the existing purification method of complex operation, time and labor consuming and higher cost. The purification method comprises: extracting the enzyme reaction liquid with an extraction system; standing and layering same, and then preserving an upper solution; and performing solvent recovery on the upper solution to obtain the product Rh2. The extraction system consists of ammonium sulfate, ethanol, and ethyl acetate; the dosage of ammonium sulfate is 2-20 g/100 ml of the enzyme reaction liquid; the overall volume of ethanol and ethyl acetate is 0.5-5 times the volume of the enzyme reaction liquid.
C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
JIANGXI BONTAC GREEN-BIOCATALYSIS ECOINDUSTRIAL PARK CO., LTD. (China)
Inventor
Zhang, Qi
Zhang, Dongmin
Fu, Rongzhao
Abstract
A purification process of NADPH is used for purifying a crude NADPH product obtained by biocatalytic preparation. The present invention resolves the technical problems of existing ion exchange resin methods having low yields and low purity of purified products. The purification method sequentially includes the following steps: pretreatment, filling an ion column, cation elution, pre-elution, product elution, concentration and drying, etc. The purity of purified NADPH is up to 98% and the yield is 85% or more.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
50.
Method for preparing nicotinamide mononucleotide (NMN)
The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by bioanalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
A nicotinamide phosphoribosyltransferase mutant and an application thereof, relating to a nicotinamide phosphoribosyltransferase mutant artificially obtained via a gene site-directed mutagenesis method and an application thereof. The purpose of the present invention is to solve the problems in the prior art that nicotinamide phosphoribosyltransferase catalytic activity is low and the value of industrial application is low. The present invention provides a series of nicotinamide phosphoribosyltransferase mutants and corresponding nucleotide sequences, an expression vector and a living cell. The enzyme catalytic activity of the mutants for the substrates nicotinamide and PRPP is 1.2-6.9 times that of their parent, and the mutants may be applied in a process of preparing nicotinamide mononucleotide.
Disclosed is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, pyrophosphoric acid or a salt thereof and inosinic acid or a salt thereof react under the catalytic effects of nicotinamide phosphoribosyltransferase, hypoxanthine phosphoribosyltransferase and xanthine oxidase so as to obtain nicotinamide mononucleotide.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 19/00 - Preparation of compounds containing saccharide radicals
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
53.
PURIFICATION METHOD FOR NICOTINAMIDE MONONUCLEOTIDE
A purification method for nicotinamide mononucleotide, relating to a method for purifying an NMN crude product obtained via a biocatalysis method. The purpose of the present method is to solve the problems in existing NMN purification methods of low yield and low purified product purity. The present method comprises the following steps: A, placing a nicotinamide mononucleotide crude product obtained via a biocatalysis method in an anion exchange resin column, eluting with water, and collecting an eluate; B, performing nanofiltration concentration treatment on the eluate of step A, and collecting a concentrate; C, placing the concentrate of step B in a chelating resin column, eluting with water, and collecting an eluate; D, performing concentration and drying treatment on the eluate of step C, and obtaining a purified nicotinamide mononucleotide product. The present method is universally applicable for the purification of NMN crude products obtained via biocatalysis methods.
Disclosed is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP and xylose react under the catalytic effects of nicotinamide phosphoribosyltransferase, ribose phosphate pyrophosphokinase, ribose-5-phosphate isomerase, ribulose-3-phosphate isomerase, xylulokinase and xylose isomerase so as to obtain nicotinamide mononucleotide.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 19/00 - Preparation of compounds containing saccharide radicals
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
Disclosed is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, pyrophosphoric acid or a salt thereof and AMP react under the catalytic effects of nicotinamide phosphoribosyltransferase and adenine phosphoribosyltransferase so as to obtain nicotinamide mononucleotide.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 19/00 - Preparation of compounds containing saccharide radicals
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
Disclosed is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP and AMP react under the catalytic effects of nicotinamide phosphoribosyltransferase, ribose phosphate pyrophosphokinase and AMP nucleosidase so as to obtain nicotinamide mononucleotide.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 19/00 - Preparation of compounds containing saccharide radicals
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Starch for industrial purposes; diastase for industrial
purposes; enzyme preparations for industrial purposes;
enzymes for industrial purposes; ferments for chemical
purposes; industrial chemicals; biochemical catalysts;
chemical reagents, other than for medical or veterinary
purposes; chemical substances for preserving foodstuffs.
58.
METHOD FOR PREPARING NICOTINAMIDE MONONUCLEOTIDE 2
Provided is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP, and ribose react under the catalytic effects of nicotinamide phosphoribosyltransferase, phosphoribose pyrophosphokinase, and ribokinase so as to obtain nicotinamide mononucleotide.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
[ Starch for industrial purposes; diastase for industrial purposes; enzyme preparations for industrial purposes; ] enzymes for industrial purposes; [ ferments for chemical purposes;] industrial chemicals [ ; biochemical catalysts; chemical reagents, other than for medical or veterinary purposes; chemical substances for preserving foodstuffs]
60.
Use of NADH or salt thereof in preparation of drugs or health-care products for treating phenylketonuria
Disclosed is use of nicotinamide adenine dinucleotide (NADH) or a salt thereof in the preparation of drugs or health-care products for treating phenylketonuria (PKU), wherein a single dose of the NADH or a salt thereof is 1-100 mg.
USE OF NICOTINAMIDE MONONUCLEOTIDE IN PREPARING MEDICATIONS FOR PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, AND MEDICATION THEREOF
A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
62.
Method for purifying reduced form of β-nicotinamide adenine dinucleotide
A method for purifying a salt of reduced form of β-nicotinamide adenine dinucleotide (NADH) includes: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction, collecting a concentrate for use; adding an ion pair reagent to the concentrate, and purifying by gradient elution to obtain a purified filtrate using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; changing the cations in the purified filtrate into sodium ions to obtain a filtrate by using a cation exchange resin; and nanofiltrating the filtrate, and freeze drying in a vacuum freeze drier. The method results in an excellent purity and yield of a salt of NADH that meets requirements in industry.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
63.
Method for purifying beta-nicotinamide mononucleotide
A method for purifying β-nicotinamide mononucleotide (NMN) includes: sequentially microfiltrating and nanofiltrating a crude product solution containing NMN using membrane concentration devices to obtain a concentrated crude product solution; adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B, to obtain a purified sample solution; concentrating the purified sample solution by nanofiltration and freeze drying in a vacuum freeze drier to obtain a purified NMN.
A creatine kinase mutation, gene and use of the mutation. The mutation takes attached sequence 2 as a reference sequence, has at least one mutation selected from the 100th site, the 121st site and the 33rd site, takes creatine and adenosine triphosphate (ATP) as substrates and has a creatine kinase catalytic activity at least 50% higher than a parent. The creatine kinase mutation can be used to produce phosphocreatine.
An application of nicotinamide adenine dinucleotide (NADH) and nicotinamide mononucleotide (NMN) in the preparation of a drug or health care product treating Parkinson's disease, β-NADH and β-NMN being prepared via enzyme catalysis.
An application of nicotinamide mononucleotide in the preparation of an anti-aging drug or health care product, a single dose of nicotinamide mononucleotide being 1-500mg/kilogram of body weight/day, the drug or health care product being a tablet, a capsule, granules, an aqueous solution, an enteric preparation or an injection.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 39/00 - General protective or antinoxious agents
67.
NICOTINAMIDE MONONUCLEOTIDE-CONTAINING ANTI-AGING BEAUTY AND SKIN CARE PRODUCT COMPOSITION
A nicotinamide mononucleotide-containing anti-aging beauty and skin care product composition, nicotinamide mononucleotide being used as an active ingredient for application in the anti-aging beauty and skin care product composition.
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated nicotinamide adenine dinucleotide phosphate solution and obtaining a concentrated crude solution; b. adjusting the pH value of the obtained crude solution to be from 2 to 4, injecting sample and applying a preparation column for reversed-phase high performance liquid chromatography, and performing purification by gradient elution to obtain a purified sample solution; c. using the membrane concentration equipment to perform nanofiltration on the purified sample solution, using a vacuum freeze dryer to perform lyophilization, and obtaining purified nicotinamide adenine dinucleotide phosphate. The nicotinamide adenine dinucleotide phosphate prepared using the present invention has high purity, high yield, and good market prospect.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
Disclosed is a method for purifying oxidized β-nicotinamide adenine dinucleotide, comprising the steps: using a filter membrane to perform microfiltration and nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting the concentrated solution for further use; adding an acid to the concentrated filtrate so as to adjust the pH value of the concentrated solution, and performing purification by means of gradient elution using a reversed-phase chromatographic column as the stationary phase, a buffer salt solution as phase A, and ethanol as phase B; using a filter membrane to perform nanofiltration and concentration on the purified solution, and then using a vacuum freeze dryer to perform lyophilization. The present invention uses reversed-phase high performance liquid chromatography to purify oxidized β-nicotinamide adenine dinucleotide, resulting in highly pure oxidized β-nicotinamide adenine dinucleotide with good yield that meets the industrialization requirements.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
Disclosed is a method for purifying reduced β-nicotinamide adenine dinucleotide, comprising the steps: performing microfiltration and then nanofiltration on a reaction liquid obtained from an enzyme catalysis reaction, and collecting the concentrated solution for further use; adding an ion pair reagent to the concentrated solution, and performing purification by means of gradient elution using a reversed-phase chromatographic column as the stationary phase, a buffer salt solution as phase A, and ethanol as phase B; using cation exchange resin to convert the cations in the purified filtrate into sodium ions; performing nanofiltration on the filtrate obtained from the steps above, and finally using a vacuum freeze dryer to perform lyophilization. The present invention uses reversed-phase high performance liquid chromatography and cation exchange to purify reduced β-nicotinamide adenine dinucleotide, resulting in highly pure reduced β-nicotinamide adenine dinucleotide with good yield that meets industrialization requirements.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
Disclosed is a purification method for β-nicotinamide mononucleotide, comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a pre-treated β-nicotinamide mononucleotide solution and collecting a concentrated crude solution; b. adjusting the pH value of the obtained crude solution to be from 3 to 7, injecting sample and applying a preparation column for reversed-phase high performance liquid chromatography, the stationary phase being octadecylsilane bonded silica, the mobile phase A being a solution having the pH value from 3 to 7 formulated using a hydrochloride solution, the mobile phase B being ethanol, and performing purification by gradient elution to obtain a purified sample solution; c. using the membrane concentration equipment to perform nanofiltration on the purified sample solution, using a vacuum freeze dryer to perform lyophilization, and obtaining purified β-nicotinamide mononucleotide.
Use of reduced nicotinamide adenine dinucleotide (NADH) or salt thereof in preparing a drug or health care product for phenylketonuria treatment, a single dose of the NADH or salt thereof being 1-100 mg.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
